Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2007 June;51(2) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2007 June;51(2):139-51

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413


eTOC

 

REWIEWS  MOLECULAR IMAGING IN PHARMACOLOGY


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2007 June;51(2):139-51

Copyright © 2007 EDIZIONI MINERVA MEDICA

lingua: Inglese

Radiolabelled chemotherapeutics

Rottey S. 1, Signore A. 2, 3, Van De Wiele C. 4

1 Division of Medical Oncology Gent University Hospital, Gent, Belgium
2 Department of Nuclear Medicine La Sapienza University of Rome, Rome, Italy
3 Department of Nuclear Medicine and Molecular Imaging University Medical Center of Groningen University of Groningen, Groningen, The Netherlands
4 Department of Nuclear Medicine Gent University Hospital, Gent, Belgium


FULL TEXT  


During the past 3 decades various chemotherapeutics have been directly or indirectly radiolabeled for single photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging. Several of these radiolabeled chemotherapeutics have been injected into patients for the purpose of better understanding their biodistribution and metabolism and to assess whether there exists a relationship between their uptake in tumor tissue and response to treatment. Based on available data, it may be concluded that PET or SPECT imaging with radiolabeled chemotherapeutics provides valuable information that helps to better understand the mechanism of action and the metabolic conversion of unlabeled chemotherapeutics in humans and that helps to provide a rationale for the lack of response to certain chemotherapeutics or for the beneficial effect of biomodulating agents. As for their utility as predictors of response to therapy, their utility is limited to those agents given in monotherapy.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail